Pure Global

SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer - Trial NCT06373133

Access comprehensive clinical trial information for NCT06373133 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by West China Hospital and is currently Not yet recruiting. The study focuses on Colorectal Cancer. Target enrollment is 36 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06373133
Phase 1/2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06373133
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer
An Exploratory Clinical Trial of SHR-8068 Combined With Aldebelizumab and BP102 in the Treatment of Refractory Colorectal Cancer

Study Focus

Colorectal Cancer

SHR-8068

Interventional

drug

Sponsor & Location

West China Hospital

Timeline & Enrollment

Phase 1/2

May 01, 2024

Nov 01, 2026

36 participants

Primary Outcome

Dose-limiting toxicity,PFS

Summary

To evaluate the efficacy and safety of SHR-8068 and Adebrelimab in Combination With
 Bevacizumabin in the treatment of microsatellite stable (MSS) advanced colorectal cancer.

ICD-10 Classifications

Malignant neoplasm of colon
Malignant neoplasm: Descending colon
Malignant neoplasm: Colon, unspecified
Malignant neoplasm: Ascending colon
Malignant neoplasm: Overlapping lesion of colon

Data Source

ClinicalTrials.gov

NCT06373133

Non-Device Trial